

# High yield bonds

## HY chemicals: Let's get cracking

Chief Investment Office GWM | 07 March 2019 05:24 am GMT

Thomas Rauh, CFA, Analyst, [thomas.rauh@ubs.com](mailto:thomas.rauh@ubs.com)

- High-yield chemical companies in our coverage universe performed strongly in 2015. Although revenues declined for most, lower raw material costs and overall cost improvements led to higher margins. Given our expectation of accelerating economic growth in Europe and continued low oil and gas prices, we expect this trend to continue albeit at a slower pace.
- We expect Huntsman's ratings to come under pressure while we maintain a stable credit outlook for Ineos and Perstorp. We expect Kerling to get upgraded within the next 12 months following the successful implementation of the Inovyn joint venture. Although we do not foresee much rating upside, we see value in several of Ineos's bonds, which yield 5–6% with a maturity of 3.5–4 years.
- Slower growth in Latin America and China remains our main concern, while we expect to see stronger growth in Europe and the US. The spiraling down of feedstock prices should translate to lower revenue figures as well, though earnings will likely suffer less. We also see increasing risk from debt-funded acquisitions.
- We provide an overview of the chemical industry and update our credit views on Huntsman, Ineos, Kerling and Perstorp. These companies are largely focused on the petrochemical segment, which is the main focus of this report.




Source: Fotolia

### The chemical industry in numbers

The chemical sector comprises companies that usually convert a variety of raw materials (oil, natural gas, metals, and minerals) into industrial chemicals. It generated an estimated turnover of about EUR 3.2 trillion in 2013, employing about two million people in the EU and US alone. While these two regions historically have accounted for more than 50% of global sales, the regional dispersion has undergone some significant changes over the past 10 years or so. China is now the single largest chemical producer with a market share of about 33% (compared to 8.7% in 2003), while Europe's market share has dropped to 20% followed by North America with 17%. The chemical sector has a large variety of end-products (about 70,000 different ones) and a widely dispersed consumer base ranging from automotive, healthcare, and agriculture to food, textile, and construction companies. Despite the well-diversified customer base, chemical companies tend to be cyclical given that most products are commodity-like and capacity cannot be readily adjusted in response to changes in demand.

**Fig. 1: Market share by geography**



Source: CEFIC, UBS, as of 2013.

### Segments within the industry


The chemical industry can be broadly split into three segments: base chemicals, specialty chemicals, and consumer chemicals. Base chemicals make up the largest segment, with about 60% of total sales. They can be further segregated into petrochemicals and their polymers and basic inorganic chemicals. These products are usually produced in very large quantities and mainly sold to the chemical industry itself or to other industries before becoming consumer products. Most companies within our coverage universe are active in the petrochemical and polymer segments, which will be the focus of this report.

*Petrochemical* companies are engaged in the manufacture of base chemicals by cracking long-chained carbon molecules into shorter-chain molecules. The raw materials that go into the cracking plants usually consist of naphtha (which refers to a broad variety of flammable liquid hydrocarbon mixtures) and other petroleum, natural gas, liquefied petroleum gas (LPG), and in recent years also coal and other biomass. The actual feedstock plays an important role for various petrochemical companies as it produces different proportions of base chemicals. Naphtha and gas oil produce more longer-chained molecules, while the percentage of ethylene and propylene is usually higher with the use of natural gas and LPG. The end-products from the cracking process can broadly be classified into two groups: olefins and aromatics. Olefins are hydrocarbons consisting of chains of carbon, with the shortest molecules (ethylene, propylene, and butadiene) being the major output products from the crackers. Aromatics contain carbon rings with benzene and toluene being the most prominent members of the family. These hydrocarbons then become the basis for many products used in our everyday life, ranging from plastics, synthetic rubbers, and resins to detergents and solvents.

*Polymerization* is the process of linking together short-chained base chemicals such as ethylene or propylene. In the presence of heat and a catalyst, these simple compounds (monomers) join together to form a product called polymer. While the chemical properties of these polymers usually do not change, the longer molecule structures often have a material impact on the physical properties such as hardness, melting temperature, and flexibility. Polymerization is mainly used to produce various kinds of plastics such as polyethylene, polyvinyl chloride (PVC), and higher-performance plastics like methyl di-isocyanate (MDI). Polymerization is also used to create various solvents (liquid used to dissolve or soften a solid substance), surfactants (which allow oil molecules to dissolve in water), and synthetic resins.


*Inorganic chemicals* comprise another important part of the industry and represent about 14% of total sales. They usually refer to all non-carbon-based compounds. There are a variety of products within this segment such as caustic soda (sodium hydroxide), chlorine, and hydrogen peroxide. Within our coverage, only Kerling and Huntsman have some minor operations within this segment through the production of caustic soda and titanium dioxide, respectively. Caustic soda is usually produced as a co-product in the manufacturing process of chlorine from rock salt. It is used in many areas such as pulp and paper production, water treatment, and other applications in the chemical industry such as the production of soaps and bleaches. Titanium dioxide is usually mined and used to enhance brightness and opacity in paints, coatings and other products.

**Fig. 2: Indicative end consumer of European chemicals**



Source: CEFIC, UBS, as of 2013.

**Fig. 3: EU chemical production growth by sector**




Source: CEFIC, UBS, as of 2013.

*Specialty chemicals* are not clearly defined, but usually refer to chemicals that are produced in smaller quantities. They comprise everything from paints and inks to crop protection, dyes, and pigments. Although individual volumes tend to be small, they still represent 27% of total sales in the EU.

*Consumer chemicals* are chemicals that are sold directly to the final consumer and not used as intermediates in other industries. These include soaps, detergents, perfumes, and cosmetics. The sector is the smallest within the chemical industry, making up about 12% of total sales.

**Fig. 4: Petrochemical value chain**



Source: UBS


### Economic drivers and costs

The industry is characterized by its strong cyclical nature caused by significant shifts in demand and supply. When economies grow, demand for chemicals starts to increase which subsequently leads to new capacity being built. Given the relatively long lead times and sizable scale of operations involved, supply cannot easily be adjusted once demand fades. Therefore, large swings in chemical prices and company operating margins are relatively common. Historically, the industry has grown at a rate 1.25 times the GDP growth rate, although actual multiples vary among segments, with specialty chemicals usually having higher growth rates. Bulk-produced and low-grade chemicals in the ethylene and propylene cycles tend to grow at lower rates.

Most of the chemical industry is very much commoditized with little room for price differentiation. This is especially true for base chemicals like petrochemicals and their polymers. Technical barriers to entry and brand and patent protection are higher for special chemicals in the biotech and pharmaceutical industries, but are very low for the greater part of the sector. As chemicals are important to a variety of industries, indicators such as manufacturing purchasing managers' indices (PMIs), construction activity, and vehicle production can give a good indication of demand.

With very little pricing power, chemical companies depend on cost advantages and economies of scale for margins and profitability. Input costs play an especially crucial role as raw materials make up about 40–60% of total costs. As mentioned before, olefins and aromatics can be derived from natural gas, LPG, or naphtha, and the choice and availability

**Fig. 5: Chemical sector cyclical growth**  
Annual growth, in %



Source: CEFIC, UBS, as of 2013.

of feedstock significantly affect profitability. Ethylene production is of special importance as it is the base chemical for about 60% of all other organic derivatives. Ethylene derived from light ethane or propane gas is usually cheaper than that derived from naphtha. Thus, ethylene production costs vary across regions, with the Middle East and the US being cheaper than Europe or Asia, which have to rely more on naphtha. While the overall level of feedstock prices affects profitability in the short term, the competitive nature of the industry tends to adjust for these relatively quickly, passing on benefits to the customers.

After feedstock, labor is the second-largest expense and represents about 20% of total costs. The production of chemicals is also energy-intensive, with direct energy costs accounting for another 5–10% of the total. That said, cost structures vary within the industry as chemical companies have different operational and capital structures. In general, however, the industry is capital-intensive, demanding proportionally higher fixed costs.


### Performance and outlook

2015 was a relatively good year for the chemical companies in our coverage universe, despite several challenges. Lower prices and volumes were largely offset by a sharp drop in raw material costs. While olefins and aromatics prices declined between 30% and 40% during the year, it was mostly on the back of a 50% decline in feedstock prices. As a result, although revenues declined for most companies, cost improvements and lower raw material costs led to higher margins, which positively affected the credit metrics of the issuers in our coverage. On the downside, companies are increasingly struggling with muted demand especially in Europe, Latin America, and increasingly in China as well.

For 2016, we expect trading conditions to remain difficult in both the petrochemical and inorganic sectors. Most companies do not anticipate much improvement and see volumes growing by less than 1%, with prices likely falling further. For ethylene-related products, we are somewhat more optimistic as several outages in Europe have supported margins as inventories remain low. European chemicals also benefit from strong currency tailwinds, which further support margins. We see the main risk for the current year coming from a significant slowdown in China and further deterioration in LatAm. The spiraling down of feedstock prices should translate to lower revenue figures as well, though earnings will likely suffer less. We also see increasing risk from debt-funded acquisitions, which remain on the agenda of most companies as organic growth is difficult to achieve in this environment.

**Fig. 6: Petrochemical prices**

In USD per mt



Source: Bloomberg, UBS, as of 2015

## Huntsman Corporation (HUN)

### Strengths

- Significant scale and geographic diversity. The group has operations spread across more than 30 countries and holds market-leading positions in many of its key products.
- Large product portfolio across different regions and end-consumers contributes to the resilience of EBITDA margins.
- Access to lower-cost, natural-gas-based feedstock in the US.
- Ample liquidity and no near-term bond maturities.

### Risks

- The group faces considerable operational risks related to maintaining a large number of chemical facilities and their logistics.
- Growth has historically been achieved through acquisitions, which could put pressure on the company's credit metrics.
- Profitability of the titanium dioxide (TiO<sub>2</sub>) business is still very low, making a planned separation or sale difficult in our view.
- Relatively shareholder-friendly policy, in combination with low free cash flow, limits room for deleveraging in our view.

### Latest results

3Q15 results were relatively weak across segments. Limited demand growth in China, strong exports out of Asia, adverse foreign exchange effects due to the US dollar's appreciation, and an outage in one of the company's facilities all negatively affected performance. Revenues declined by 9% year-over-year as prices of polyurethane, performance products, and pigments fell by more than 10% while volumes were relatively mixed. EBITDA declined by 13% to USD 256m (9.7% margin), largely in line with revenues. Operating cash flows dropped by USD 154m to USD 206m, with free cash flows turning negative in a historically strong quarter. We expect further deterioration in the fourth quarter, which usually suffers from a seasonal slowdown.

### Credit view

We maintain our deteriorating credit outlook given the weak profitability in the pigments and especially the TiO<sub>2</sub> segment (21% of revenues) as well as the weaker-than-expected results in the important polyurethanes division (37% of revenues). Low capacity utilization, weak demand, and growing exports from China will continue to put pressure on prices, in our view. In addition, Huntsman is adversely affected by the strong USD, and the low oil price reduces its US Gulf Coast cost advantage (from cheaper natural gas). Although we see some room for improvement especially through the company's planned restructuring program in the pigments and additives businesses (accumulated cost savings of USD 250m until 2016), we remain skeptical that it will be sufficient to maintain the company's current credit rating. Management intends to separate the pigments business, but given the negative EBITDA contribution we do not think a sale or IPO is feasible at this time..

Following the acquisition of Rockwood in October 2014, Huntsman's credit metrics have continued to deteriorate, with net leverage spiking at 5.3x as of 3Q15. While management still guides for a net leverage target of 2–2.5x, we view the target as unachievable in the near future given the limited cash generation. While management plans to improve cash flows

**Fig. 7: Issuer profile**

Sub-asset class	High Yield
Industry/Sector:	Material
Country:	United States
Moody's:	Ba3, stable
S&P:	BB-, stable
Fitch:	n.a.

### CIO Credit risk flags

Senior unsecured


< 2 y      2-5 y      5-10 y      > 10 y



**Issuer credit outlook**      Deteriorating

Source: Bloomberg, UBS, as of 12 January 2016

**Fig. 8: Revenue by division**



Source: UBS, company reports, as of 3Q 2015.

### Company Description

Huntsman Corporation is a diversified chemicals company with operations in 30 countries across six continents. Huntsman's business is organized into five segments: Polyurethanes, Performance Products, Advanced Materials, Pigments, and Textile Effects. The company has market-leading positions in products such as MDI, amines, epoxy-polymers, surfactants and titanium dioxide (TiO<sub>2</sub>). The group is publicly listed and the Huntsman family is the largest shareholder.

by at least USD 350m in 2016 through capital expenditure reductions, restructuring, and lower maintenance spending, we remain skeptical of its ability to lower its leverage, which is currently above Moody's target (<4.5x) for a Ba3 rated company. Absent a meaningful recovery in TiO<sub>2</sub> prices and stronger demand for its polyurethanes, we therefore see a high chance for a downgrade of Huntsman over the next 12 months. In addition, the company recently announced a USD 150m share repurchase program.


Despite the drop in liquidity since the beginning of the year, we still view Huntsman's liquidity as adequate. As of 3Q15, the company had USD 433m in cash, a USD 625m undrawn revolving credit facility, and about USD 250m available under its securitization facilities. With a guided free cash flow of USD 350m and no significant debt maturities in 2016, we expect Huntsman to be able to meet all its liabilities in the near future. Its next bond maturity is 2020, which gives it ample time to address its current issues. However, we note that more than half of Huntsman's debt ranks senior to these bonds, reducing the recoverable amount in the case of a potential default. Both Moody's and S&P therefore rate the group's bonds lower than its corporate credit rating.

### Investment view

Despite the recent drop in Huntsman bond prices, we do not recommend adding exposure to the company. We expect the bonds to remain volatile and could see further pressure should our expected rating downgrade materialize. We would like to see some stabilization in the company's TiO<sub>2</sub> segment and some improvement of the credit metrics before we consider making an investment. We therefore maintain our fair value view on the company's liquid on the bonds.

**Fig. 9: EBITDA development by division**

In USD million



Source: UBS, company reports, as of 3Q 2015.

**Table 1: Company bonds**

CIO view	Issuer	ISIN	Ccy	Cpn	Amt. Out. (M)	Maturity	Ratings (S&P / Fit. / Mdy)	Ind. Off. Pr.	YTM	YTW	ASW	Next call date	Next call px
fair	HUNTSMAN INTERNATIONAL L	US44701QAZ54	USD	4.875	650	15/11/2020	B / n.a. / B1	92.3	6.8%	6.8%	494	15/08/2020	100.0
fair	HUNTSMAN INTERNATIONAL L	XS1056202762	EUR	5.125	443	15/04/2021	B / n.a. / B1	91.5	7.1%	7.1%	636	15/01/2021	100.0
illiquid	HUNTSMAN INTERNATIONAL L	USU44657AR22	USD	5.125	400	15/11/2022	B / n.a. / B1	91.3	6.7%	6.7%	465	15/08/2022	100.0
fair	HUNTSMAN INTERNATIONAL L	XS1207638732	EUR	4.250	300	01/04/2025	B / n.a. / B1	80.4	7.2%	7.2%	552	01/01/2025	100.0

Source: Bloomberg, UBS, as of 12 January 2016

**Table 2: Summary of financial information**

	<b>FY Dec 2010</b>	<b>FY Dec 2011</b>	<b>FY Dec 2012</b>	<b>FY Dec 2013</b>	<b>FY Dec 2014</b>	<b>LTM Sept 2015</b>
USD, million	12 months	12 months	12 months	12 months	12 months	12 months
Revenue	9,250	11,221	11,187	11,079	11,578	10,918
EBITDA	647	1,045	1,192	894	1,032	839
EBIT	410	606	845	510	633	457
Interest expense	203	204	209	187	208	221
Net income	32	254	373	149	345	82
Funds from operations (FFO)	697	700	930	741	854	636
Working capital	-755	-335	-156	-33	-94	168
Cash flow from operations (CFO)	-58	365	774	708	760	804
Capex	263	356	539	575	709	813
Disposal of businesses	-27	-26	-127	-104	-108	-109
Free cash flow	-321	9	235	133	51	-9
Dividends	-6	-8	-96	-120	-121	-122
Cash & short investments	966	554	387	520	860	433
Total debt	4,146	3,942	3,702	3,910	5,200	4,867
Net debt	3,180	3,388	3,315	3,390	4,340	4,434
EBITDA margin	7.0%	9.3%	10.7%	8.1%	8.9%	7.7%
EBIT margin	4.4%	5.4%	7.6%	4.6%	5.5%	4.2%
EBITDA/cash interest expense	3.2x	5.1x	5.7x	4.8x	5.0x	3.8x
Debt/EBITDA	6.4x	3.8x	3.1x	4.4x	5.0x	5.8x
Net debt/EBITDA	4.9x	3.2x	2.8x	3.8x	4.2x	5.3x
FFO/net debt	21.9%	20.7%	28.1%	21.9%	19.7%	14.3%
FCF/net debt	-10.1%	0.3%	7.1%	3.9%	1.2%	-0.2%

Source: UBS, company reports, as of 3Q 2015.

## Ineos Group Holding S.A. (INEGRP)

### Strengths

- Significant scale and geographic diversity. Ineos is one of the world's largest petrochemical companies with leading market positions in many of its key products.
- Significant degree of vertical integration reduces supply and input-cost volatility.
- US business and increasingly Europe benefit from access to cheaper natural gas feedstock.
- Well-diversified customer base among various different industries.

### Risks

- Cyclical business with commodity-like products which give limited pricing power.
- Exposure to volatile commodity prices. The group's costs and pricing are highly related to oil and gas prices.
- High leverage, and management remains open to opportunistic acquisitions.
- Relatively complex corporate structure with several intercompany loan agreements and business transactions in the wider group, which decreases transparency.

### Latest results

Despite a significant 24% decline in revenues, Ineos greatly improved its profitability in 3Q15 as EBITDA increased by 14%. Revenues declined mainly on the back of lower oil prices which led to a subsequent decline in olefin prices both in Europe and the US. On the other hand, Ineos benefited from higher sales volumes and the appreciation of the USD. The North American business continues to benefit from the current feedstock advantage, while several outages by some European competitors limited supply and favorably affected prices. The improved profitability also led to significantly higher cash generation despite the company's acquisition of the remaining 50% interest in the Noretyl cracker for a gross consideration of EUR 200m. As a result, net debt declined by about EUR 176m with net leverage down 0.6x to 2.8x.

### Credit view

We have a stable credit outlook on Ineos Group Holdings (IGH). The group benefits from its strong market position as one of the world's largest petrochemical companies, its vertical integration, and beneficial supply economics. Ineos's facilities tend to be of high value, operating at lower costs, and are closely integrated with supplying refineries or connected to olefin-derivatives units. This saves IGH substantial logistics costs and enables it to capture margins across the value chain. The company's capex on system upgrades and capacity improvements also gives it a distinct advantage. Its crackers, for example, can switch to some extent between naphtha and gas as a feedstock, enabling it to adjust to pricing imbalances. Moreover, the company has invested in infrastructure to buy cheaper gas from the US for its European operations, which gives it a distinct advantage over its competitors. The current low feedstock prices and relatively high olefin margins have also helped greatly in improving profitability. That said, we think this trend will eventually reverse especially in light of significant planned capacity additions both in the US and Asia over the medium term.

**Fig. 10: Issuer profile**

Sub-asset class	High Yield
Industry/Sector:	Material
Country:	Switzerland
Moody's:	B3, stable
S&P:	B+, stable
Fitch:	n.a.

### CIO Credit risk flags

Senior unsecured

< 2 y      2-5 y      5-10 y      > 10 y




### Issuer credit outlook

Stable

Source: UBS, Bloomberg, as of 12 January 2016.

**Fig. 11: Turnover by application**



Source: UBS, company reports, as of 3Q 2015.

### Company Description

Ineos Group is a large diversified petrochemical company engaged primarily in the olefins value chain (base chemicals and plastics) and holds leading positions in key market segments. Ineos operates three business divisions: Olefins and Polymers (O&P) Europe, O&P North America, and Chemical Intermediates. The group is controlled by James A. Ratcliffe (71%), Andrew Currie (14%), and John Reece (14%) through their shareholding in the issuer's ultimate parent company Ineos AG, which is incorporated in Switzerland.




Although gross leverage has declined to 3.7x from 4.1x at the beginning of the year on the back of higher EBITDA, we note that the company has been unable to significantly reduce net debt levels. We continue to view its current capital structure as highly leveraged. With EBITDA growth mostly driven by the US business (EBITDA margin of 36.8% in 3Q15), which currently benefits from the unusually low feedstock prices in combination with relatively high olefin spreads, we expect margins to contract again in the next 2–3 quarters. Free cash flow generation, which has historically been very low, significantly improved to about EUR 1.2bn as of the last 12 months (LTM) through 3Q15. We expect cash generation to remain stronger in the near future as Ineos continues to benefit from the aforementioned tailwinds.

We view the company's liquidity as adequate with about EUR 2.1bn in cash and cash equivalents and EUR 141m available under its EUR 1bn working capital facility. We expect the company to continue to generate positive free cash flow over the next 12 months. Ineos has no significant debt maturities in 2016 with the exception of its securitization facility, which we expect to be extended during the year.

### Investment view

Since the beginning of the year, most high-beta bonds have traded off markedly. While we do not see much rating upside for the company, we still consider its shorter-dated bonds to be attractive investments, especially following the recent drop in bond prices. We change our view on the EUR 6.5% 2018, USD 6.125% 2018, and EUR 5.75% 2019 bonds to attractive from fair. We continue to view the remaining bonds as fairly valued.

**Fig. 12: Turnover by geography**



Source: UBS, company reports, as of FY 2014.

**Table 3: Company bonds**

CIO view	Issuer	ISIN	Ccy	Cpn	Amt. Out. (M)	Maturity	Ratings (S&P / Fit. / Mdy)	Ind. Off. Pr.	YTM	YTW	ASW	Next call date	Next call px
attractive	INEOS GROUP HOLDINGS SA	XS0928189777	EUR	6.500	500	15/08/2018	B- / n.a. / B3	101.4	5.9%	5.4%	548	11/02/2016	103.3
attractive	INEOS GROUP HOLDINGS SA	USL5078PAA59	USD	6.125	678	15/08/2018	B- / n.a. / B3	99.8	6.2%	6.2%	499	11/02/2016	103.1
attractive	INEOS GROUP HOLDINGS SA	XS0982710740	EUR	5.750	600	15/02/2019	B- / n.a. / B3	99.7	5.9%	5.9%	576	15/02/2016	102.9
fair	INEOS GROUP HOLDINGS SA	USL5078PAD98	USD	5.875	590	15/02/2019	B- / n.a. / B3	99.1	6.2%	6.2%	485	15/02/2016	102.9
fair	INEOS FINANCE PLC	XS1117296209	EUR	4.000	770	01/05/2023	BB- / n.a. / Ba3	93.9	5.0%	5.0%	420	01/05/2018	102.0

Source: Bloomberg, UBS, as of 12 January 2016

**Table 4: Summary of financial information**

	<b>FY Dec 2009</b>	<b>FY Dec 2010</b>	<b>FY Dec 2011</b>	<b>FY Dec 2012</b>	<b>FY Dec 2013</b>	<b>FY Dec 2014</b>	<b>LTM Sept 2015</b>
EUR, million	12 months	12 months	12 months	12 months	12 months	12 months	12 months
Revenue	12,111	16,008	17,586	18,188	16,623	17,221	14,827
EBITDAR	1,693	2,155	2,037	1,704	1,852	2,222	2,564
EBITDA	1,062	1,645	1,714	1,417	1,504	1,870	2,212
EBIT	404	1,149	1,224	492	1,073	1,447	1,808
Interest expense	730	763	655	673	565	433	539
Net income	-659	-57	376	-287	-134	-37	643
Funds from operations (FFO)	449	770	1,028	601	600	1,042	1,408
Working capital	48	-478	-518	-144	-148	-54	230
Cash flow from operations (CFO)	497	292	509	457	452	988	1,638
Capex	268	344	396	462	544	425	421
Disposal of businesses	-32	415	664	0	0	122	201
Free cash flow	229	-53	113	-4	-92	564	1,217
Dividends paid	0	23	14	25	34	66	66
Cash & short investments	662	599	582	1,235	1,130	1,435	2,130
Adj. debt	12,994	11,604	9,437	10,005	10,306	10,832	11,380
Total debt	7,749	7,343	6,593	7,289	7,240	7,708	8,227
Net debt	7,087	6,744	6,011	6,054	6,110	6,273	6,097
EBITDA margin	8.8%	10.3%	9.7%	7.8%	9.0%	10.9%	14.9%
EBIT margin	3.3%	7.2%	7.0%	2.7%	6.5%	8.4%	12.2%
EBITDA/cash interest expense	1.5x	2.2x	2.6x	2.1x	2.7x	4.3x	4.1x
Adj. debt/EBITDAR	7.7x	5.4x	4.6x	5.9x	5.6x	4.9x	4.4x
Debt/EBITDA	7.3x	4.5x	3.8x	5.1x	4.8x	4.1x	3.7x
Net debt/EBITDA	6.7x	4.1x	3.5x	4.3x	4.1x	3.4x	2.8x
FFO/net debt	6.3%	11.4%	17.1%	9.9%	9.8%	16.6%	23.1%
FCF/net debt	3.2%	-0.8%	1.9%	-0.1%	-1.5%	9.0%	20.0%

Source: UBS, company reports, as of 3Q 2015.

## Kerling (KERLIN)

### Strengths

- Largest producer of PVC and caustic soda in Europe and third-largest worldwide.
- Competitive cost base through supply agreements with parent company Ineos.
- Expected synergies from the Inovyn joint venture with Solvay through streamlined product mix, improved production processes, and optimized raw material purchases.
- Joint venture with Solvay strongly improved credit metrics.

### Risks

- Cyclical business with strong competitive pressure. Kerling's principal output products (PVC and caustic soda) are commodity chemicals and exhibit cyclical business dynamics.
- Planned future exit of Solvay will likely increase leverage significantly.
- Less diversified business model and stronger reliance on outside ethylene supply after the asset sales.
- Weak free cash generation owing to high debt servicing costs.

### Latest results

Although comparison is somewhat limited due to the Inovyn formation as well as several asset disposals, Kerling reported relatively good 3Q15 results. Although revenues declined by EUR 141m to EUR 887m (or by EUR 12m to EUR 818m excluding the disposal of remedy assets), profitability greatly improved. The decline was largely volume-driven as sales prices for both PVC and caustic soda increased, while PVC volumes declined on the back of weaker demand and an outage at one of Kerling's facilities. However, the decline in revenues was more than offset by large cost savings. A 14% decline in ethylene prices in combination with a weaker EUR significantly improved profitability. EBITDA for the quarter increased by 148% y/y to EUR 134m (15.2% margin). Operating cash flow declined to EUR 48m (from EUR 94m in 3Q14) largely due to adverse working capital movements (a concern when feedstock and inventory prices are falling). Net debt declined slightly (by at least 10%) to EUR 890m (EUR 956m, as of FY2014) driven by the asset disposal.

### Credit view

We change our credit outlook on Kerling to improving from stable following the formation of the Inovyn JV which, in combination with the strong results, led to a significant improvement of the company's credit metrics. We expect earnings to continue to grow, supported by increasingly low feedstock prices and ongoing synergies between the two JV partners. Increased specialization of their plants, better pricing power for the purchase of raw materials and energy, as well as cost savings from a combined marketing and sales force should support margins. The ongoing European recovery should also lead to higher demand in the construction industry, which is one of the main end-consumers of many of its chlor-vinyl products. Although the company's caustic soda division showed signs of improvement, we remain cautious as the pulp and paper industry (one of the key consumers of caustic soda) in Europe is still in a structural decline. Overall we are optimistic about the business outlook, but still see downside risks due to the high cyclicity of the industry.

**Fig. 13: Issuer profile**

Sub-asset class	High Yield
Industry/Sector:	Material
Country:	United Kingdom
Moody's:	Caa1, watch +
S&P:	B-, positive
Fitch:	n.a.

### CIO Credit risk flags

Senior unsecured

< 2 y      2-5 y      5-10 y      > 10 y




### Issuer credit outlook

Improving

Source: UBS, Bloomberg, as of 12 January 2016.

**Fig. 14: Revenues by region**



Source: UBS, Company reports, as of FY 2014.

### Company Description

Kerling is one of the leading Western European producers of PVC, caustic soda, and caustic potash as well as brine and water chemical products. On 1 July 2015, most of Kerling's chlor-vinyls activities were brought into a joint venture with a subsidiary of Solvay SA. The joint venture is named Inovyn and operates 17 sites in eight countries. Kerling is indirectly owned by INEOS AG and is based in the United Kingdom.

Kerling's net leverage strongly improved during the past nine months to 4.3x from 8.4x at the beginning of the year. Proceeds from asset sales helped reduce net debt, while EBITDA increased by 110% on an LTM basis. Absent a severe market downturn or strong oil price recovery, we expect further EBITDA growth as synergies from the JV materialize. That said, we still view the free cash flow generation as weak and do not expect a material reduction in net debt. In addition, we see the risk of a potential releveraging once Solvay exits the JV in about three years. Overall, we still expect a rating upgrade by both S&P and Moody's from the current low levels within the next 12 months.


We view Kerling's liquidity as rather weak despite recent improvements. It had EUR 67m in cash and cash equivalents as of 30 September 2015 and EUR 10m available under its credit facility. In addition, Kerling has access to a EUR 300m receivables securitization facility, of which EUR 99.3m has been drawn. We expect liquidity to improve over the next quarters as the adverse working capital movements are expected to reverse. Absent a successful bond refinancing, we think Kerling would be unable to repay its 2017 bond, which increases the company's credit risk in our view. We therefore amend our credit risk flag to reflect this possible scenario.

### Investment view

We change our view on Kerling's 10.625% 2017 bond to expensive from fair as we expect this bond to be refinanced in the near future. The bonds become callable at par starting February, and with a current price of 100.9, we see limited value in purchasing these bonds.

**Fig. 15: Product sales volumes**

In kilotonnes



Source: UBS, Company reports, as of FY 2014.

**Table 5: Company bonds**

CIO view	Issuer	ISIN	Ccy	Cpn	Amt. Out. (M)	Maturity	Ratings (S&P / Fit. / Mdy)	Ind. Off. Pr.	YTM	YTW	ASW	Next call date	Next call px
expensive	KERLING PLC	XS0480857415	EUR	10.625	785	01/02/2017	B- / n.a. / Caa1 / *+	100.7	9.9%	1.6%	182	11/02/2016	100.0

Source: UBS, Bloomberg, as of 12 January 2016.

**Table 6: Summary of financial information**

	<b>FY Dec 2012</b>	<b>FY Dec 2013</b>	<b>FY Dec 2014</b>	<b>LTM Sept 2015</b>
EUR, million	12 months	12 months	12 months	12 months
Revenue	2,646	2,554	2,476	2,636
EBITDA	149	179	153	321
EBIT	21	25	9	170
Interest expense	99	98	99	100
Net income	-64	-54	-97	-177
Funds from operations (FFO)	46	48	41	190
Working capital	-54	76	-3	-149
Cash flow from operations (CFO)	-7	124	38	41
Capex	85	67	69	74
Disposal of businesses	4	-2	1	409
Free cash flow	-93	57	-31	-33
Cash & short investments	52	55	38	67
Total debt	1,214	1,207	1,320	1,437
Net debt	1,162	1,152	1,282	1,370
EBITDA margin	5.6%	7.0%	6.2%	12.2%
EBIT margin	0.8%	1.0%	0.3%	6.5%
EBITDA/cash interest expense	1.5x	1.8x	1.5x	3.2x
Debt/EBITDA	8.2x	6.7x	8.6x	4.5x
Net debt/EBITDA	7.8x	6.4x	8.4x	4.3x
FFO/net debt	4.0%	4.2%	3.2%	13.8%
FCF/net debt	-8.0%	4.9%	-2.4%	-2.4%

Source: UBS, company reports, as of 3Q 2015.

## Perstorp (PERHOL)

### Strengths

- Leadership position in most of its key markets and longstanding customer portfolio.
- Diversified product portfolio within niche chemical segments, where it is in most cases among the top three players.
- Above market EBITDA margins commensurate with a Ba rating and resilient sales despite cyclical end-customer industries.
- Involvement of a strong sponsor (PAI Partners) that recently sold a major equity investment, leaving it with additional cash to support the business if needed.

### Risks

- Intermediate chemical producer with a highly cyclical business and a limited ability to influence demand or profitability.
- Significant leverage in combination with low free cash flow generation limits ratings upside in our view.
- Highly exposed to changes in raw material costs as well as its reporting currency, the Swedish krona (SEK appreciation negatively affects profitability but reduces debt and interest expenses).
- Complex product portfolio. The group's wide range of products leaves it with no clear earnings driver.

### Latest results

Although revenues declined by about 2% in 3Q15 mainly due to the scheduled maintenance shutdown at one of its facilities, Perstorp reported good results. While volumes decreased by 4% compared to a year ago, organic volume-based sales increased by 3% excluding the maintenance shutdown. Sales prices decreased by 6% y/y as lower raw material prices affected prices of downstream derivatives as well. The depreciation of the Swedish krona offset most of the effect and positively contributed 7% to net sales (SEK 35m to EBITDA). Year-over-year EBITDA increased for the ninth consecutive quarter to SEK 420m (15.1% margin). Despite higher operating earnings, free cash flow decreased by SEK 294m mainly on the back of adverse working capital movements and slightly higher capex. In combination with the SEK depreciation, gross debt increased by SEK 1.6bn, but overall leverage still declined to 7.6x from 9.0x since the beginning of the year.

### Credit view

We maintain our stable credit outlook. We believe Perstorp will continue to benefit from its higher-growth niche products, well-integrated operations, and diverse product mix. In addition, we expect raw material prices to remain low and do not expect a meaningful appreciation of the SEK against the USD or EUR. We therefore see further potential for modest EBITDA growth given that 2015 results were negatively affected by several shutdowns. That said, we note that the company still operates in a highly competitive industry with a number of players such as BASF having greater financial flexibility. We therefore see increasing risk for further pricing pressure amid low oil prices.

Despite Perstorp's improved performance over the recent quarters, we currently view a rating upgrade as unlikely given the high leverage of 7.6x. The company is burdened with more than SEK 13bn, causing

**Fig. 16: Issuer profile**

Sub-asset class	High Yield
Industry/Sector:	Material
Country:	Sweden
Moody's:	Caa1, stable
S&P:	CCC+, stable
Fitch:	n.a.

### CIO Credit risk flags

Senior unsecured

< 2 y      2-5 y      5-10 y      > 10 y




### Issuer credit outlook

Stable

Source: UBS, Bloomberg, as of 12 January 2016.

**Fig. 17: Net sales by market segment**



Source: UBS, company reports, as of 3Q 2015..

### Company Description

Perstorp is a Swedish-based highly diversified intermediate specialty and fine chemical manufacturer. The group mainly focuses on additives and performance-enhancing products and caters to diverse end-markets, predominantly in coatings, plastic processing, and automotive industries. The group has a 130-year-old history and is owned by PAI Partners (86%) and the group's management and other employees (14%) through an intermediate holding company Financière Forêt S.à.r.l.


associated interest expenses of SEK 1.2bn as of LTM 3Q15. Perstorp is therefore struggling to generate meaningful cash flows, which could be used to lower the company's debt. Absent meaningful asset sales, we also see limited room for reducing the company's debt burden.

Perstorp had SEK 648m of unrestricted cash (SEK 232m restricted) in addition to SEK 418m of undrawn capacity under its revolving credit facility (SEK 550m in total). While we think liquidity for the next 12 months is adequate to meet ongoing business expenses, we note that access to the facility is subject to meeting maintenance covenants, including minimum cash interest coverage of 1.25x, maximum leverage of 9.5x, and minimum LTM EBITDA of SEK 940m. We currently see adequate headroom under all covenants. That said, liquidity could become an issue in case Perstorp is unable to refinance its outstanding bonds in due time as all of its bonds mature between May and August 2017.

### Investment view

Although Perstorp's bonds are one of the highest yielding bonds within our coverage (outside the energy sector), we currently do not deem them attractive. All of the bonds become callable starting May 2016 at par, which limits the price upside in our view. Given that all of the bonds mature in 2017, we see a higher chance for selective refinancing prior to their maturity. We therefore continue to view them as fairly valued.

**Fig. 18: Net sales by geography**



Source: UBS, company reports, as of 3Q 2015.

**Table 7: Company bonds**

CIO view	Issuer	ISIN	Ccy	Cpn	Amt. Out. (M)	Maturity	Ratings (S&P / Fit. / Mdy)	Ind. Off. Pr.	YTM	YTW	ASW	Next call date	Next call px
<b>fair</b>	PERSTORP HOLDING AB	XS0855179536	EUR	9.000	270	15/05/2017	CCC+ / n.a. / B2	100.9	8.2%	6.1%	621	11/02/2016	104.5
<b>fair</b>	PERSTORP HOLDING AB	USW64150AA84	USD	8.750	380	15/05/2017	CCC+ / n.a. / B2	98.5	10.0%	10.0%	887	11/02/2016	104.4
<b>illiquid</b>	PERSTORP HOLDING AB	USW64150AB67	USD	11.000	370	15/08/2017	CCC- / n.a. / Caa2	100.9	10.4%	8.3%	765	11/02/2016	105.5

Source: Bloomberg, UBS, as of 12 January 2016

**Table 8: Summary of financial information**

	<b>FY Dec 2010</b>	<b>FY Dec 2011</b>	<b>FY Dec 2012</b>	<b>FY Dec 2013</b>	<b>FY Dec 2014</b>	<b>LTM Sept 2015</b>
SEK, million	12 months	12 months	12 months	12 months	12 months	12 months
Revenue	10,600	11,297	10,036	10,343	11,084	11,323
EBITDA	1,649	1,544	1,277	1,095	1,269	1,717
EBIT	619	584	654	-9	633	1,036
Interest expense	673	520	468	785	1,031	1,209
Net income	-316	-405	13	-1,891	-1,786	-1,314
Funds from operations (FFO)	1,025	986	551	226	257	396
Working capital	-211	68	-384	-213	720	363
Cash flow from operations (CFO)	814	1,054	167	13	977	759
Capex	889	592	490	735	837	656
Free cash flow	-75	462	-323	-722	140	103
Cash & short investments	395	453	678	905	1,019	880
Total debt	12,264	11,147	10,522	10,436	11,420	13,011
Net debt	11,869	10,694	9,844	9,531	10,401	12,131
EBITDA margin	15.6%	13.7%	12.7%	10.6%	11.4%	15.2%
EBIT margin	5.8%	5.2%	6.5%	-0.1%	5.7%	9.1%
EBITDA/cash interest expense	2.5x	3.0x	2.7x	1.4x	1.2x	1.4x
Debt/EBITDA	7.4x	7.2x	8.2x	9.5x	9.0x	7.6x
Net debt/EBITDA	7.2x	6.9x	7.7x	8.7x	8.2x	7.1x
FFO/net debt	8.6%	9.2%	5.6%	2.4%	2.5%	3.3%
FCF/net debt	-0.6%	4.3%	-3.3%	-7.6%	1.3%	0.8%

Source: UBS, company reports, as of 3Q 2015.



## UBS CIO risk views

---

### Credit risk flags

CIO attaches a credit risk flag to the instruments under its coverage. Credit risk is assessed based on the remaining tenor and / or instrument type. The flag indicates the likelihood that a holder of the instrument will not receive a coupon or principal payment when it comes due. For subordinated and hybrid instruments, which are usually callable and have a remote or no fixed maturity date, we apply one uniform credit risk flag per issuer and instrument type. The idea is to reflect the possibility of contractual trigger events or regulatory intervention occurring. Either can impose losses on bondholders regardless of the remaining term of the instrument or a specific issuer default event. Credit risk flags only indicate our view of the riskiness of a particular instrument. Credit risk flags should not be seen as recommendations to buy, hold or sell. In fact, any combination of risk flags and relative value recommendations is possible.

#### Very low credit risk



We believe that the probability of debt payments not being made when they come due is very low (cumulative probability of less than 2%).

#### Medium credit risk



We believe that the probability of debt payments not being made when they come due is low to medium (cumulative probability of non-payment between 2% and less than 20%).

#### High credit risk



We believe that the probability of debt payments not being made when they come due is at least one in five cumulatively.

### Issuer credit outlook

We complement the instrument-specific risk information of the credit risk flags by indicating our outlook for the credit quality of an issuer over the next 12 months. Depending on instrument pricing, all combinations of an issuer credit outlook and relative valuation recommendations are possible.

**Improving:** We expect the credit profile of the issuer to improve, to an extent that may result in upgrades by rating agencies.

**Stable:** We do not expect the credit profile of the issuer to change meaningfully.

**Deteriorating:** We expect the credit profile of the issuer to deteriorate, to an extent that may result in downgrades by rating agencies.


## UBS CIO valuation views

---


### Relative value bond recommendations

Our relative value bond recommendations are based on an average investment horizon of six to 12 months. They reflect our assessment of a bond's attractiveness relative to comparable instruments under CIO coverage. Comparable instruments typically exhibit similar credit quality, are denominated in the same currency, belong to the same segment of the bond market, and have a similar remaining tenor until redemption.


Views on a particular instrument can change within the six- to 12-month time frame, and those that apply to one instrument do not necessarily apply to others of the same issuer. Views on a particular instrument may be withdrawn if it does not have a sizeable basket of comparable instruments under CIO coverage.



Bonds seen as "attractive" are expected to generate a total return exceeding the average return of comparable instruments. Our recommendation can stem from a positive view on the issuer's credit profile not fully reflected in the price, unduly high risk premiums, our take on an instrument's call probability, the risk of coupon deferrals, and external factors including regulatory intervention.



Bonds seen as "fair" are expected to produce a total return broadly in line with the average return of comparable instruments.



Bonds seen as "expensive" are expected to earn a total return that is less than the average return of comparable instruments. Our recommendation can stem from a negative view on the issuer's credit profile not fully reflected in the price, unduly tight risk premiums, our take on an instrument's call probability, the risk of coupon deferrals, and external factors including regulatory intervention.

### Sell recommendations



A Sell recommendation is assigned when the risk of an adverse outcome for an instrument exceeds what is reflected in its current valuation. Such situations can include those in which the instrument appears likely to post negative total returns until redemption, either due to a highly negative yield to maturity or an imminent call at a price below market valuations.

## Appendix

### Contact

If you require information on UBS Chief Investment Office GWM, its research publications and UBS disclosures with regard to financial instruments and/or issuers, please contact the mailbox [ubs-cio-wm@ubs.com](mailto:ubs-cio-wm@ubs.com) (note that e-mail communication is unsecured) or contact your client advisor for assistance.

### Frequency of updates

Equity recommendation lists can be updated on a daily basis, and are refreshed at least every two weeks. Risk views on bond issuers and instruments are affirmed sporadically and changed ad hoc, subject to market developments.

### Competent authority of the producer

UBS Switzerland AG is regulated by the Swiss Financial Market Regulatory Authority (FINMA). UBS Europe SE, Succursale Italia is regulated by Commissione Nazionale per le Società e la Borsa (CONSOB). UBS AG Tokyo Branch is regulated by the Financial Services Agency (FSA). UBS Asesores Mexico, S.A. de C.V. is regulated by Comisión Nacional Bancaria y de Valores (CNBV). UBS AG Singapore Branch is regulated by the Monetary Authority of Singapore (MAS). UBS Europe SE, sucursal en España is regulated by Comisión Nacional del Mercado de Valores (CNMV). UBS AG London Branch is regulated by the Prudential Regulatory Authority (PRA) and the Financial Conduct Authority (FCA). UBS AG Hong Kong Branch is regulated by the Securities and Futures Commission (Hong Kong) and the Hong Kong Monetary Authority. UBS Brasil Administradora de Valores Mobiliarios Ltda is regulated by Comissão de Valores Mobiliários. UBS Financial Services Inc. is registered as a broker-dealer with the Securities and Exchange Commission ("SEC"), a futures commission merchant with the Commodity Futures Trading Commission ("CFTC") and the National Futures Association and is a member of various exchanges and the Financial Industry Regulatory Authority ("FINRA").

### Competent authority of the disseminator

This publication has been disseminated by the UBS Group entity you have a banking relationship with. The full name of the disseminating entity and its competent authority can be found in the country-specific disclaimer at the end of this document.

### Disclosures (13 January 2016)

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to each company mentioned in the publication.

INEOS 1;

1. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

---

#### Disclaimer

For more information about our present and past recommendations, please contact [ubs-cio-wm@ubs.com](mailto:ubs-cio-wm@ubs.com).

UBS Chief Investment Office's ("CIO") investment views are prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS").

The investment views have been prepared in accordance with legal requirements designed to promote **the independence of investment research**.

#### Instrument/issuer-specific investment research – Risk information:

This publication is **for your information only** and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein does not constitute a personal recommendation or take into account the particular investment objectives, investment strategies, financial situation and needs of any specific recipient. It is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for sale to all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness (other than disclosures relating to UBS). All information and opinions as well as any forecasts, estimates and market prices indicated are current as of the date of this report, and are subject to change without notice. This publication is not intended to be a complete statement or summary of the securities, markets or developments referred to in the report. Opinions expressed herein may differ or be contrary to those expressed by other business areas or divisions of UBS as a result of using different assumptions and/or criteria.

In no circumstances may this document or any of the information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes (i) valuation or accounting purposes; (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees. By receiving this document and the information you will be deemed to represent and warrant to UBS that you will not use this document or otherwise rely on any of the information for any of the above purposes. UBS and any of its directors or employees may be entitled at any time to hold long or short positions in investment instruments referred to herein, carry out transactions involving relevant investment instruments in the capacity of principal or agent, or provide any other services or have officers, who serve as directors, either to/for the issuer, the investment instrument itself or to/for any company commercially or financially affiliated to such issuers. At any time, investment decisions (including whether to buy, sell or hold securities) made by UBS and its employees may differ from or be contrary to the opinions expressed in UBS research publications. Some investments may not be readily realizable since the market in the securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, divisions or affiliates of UBS. Futures and options trading is not suitable for every investor as there is a substantial risk of loss, and losses in excess of an initial investment may occur. Past performance of an investment is no guarantee for its future performance. Additional information will be made available upon request. Some investments may be subject to sudden and large falls in value and on realization you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information.

Research publications from **CIO** are written by UBS Global Wealth Management. **UBS Investment Research** is written by UBS Investment Bank. Except for economic forecasts, the research process of **CIO** is independent of **UBS Investment Research**. As a consequence research methodologies applied and assumptions made by **CIO** and **UBS Investment Research** may differ, for example, in terms of investment horizon, model assumptions, and valuation methods. Therefore investment recommendations independently provided by the two UBS research organizations can be different.

## Appendix

### Disclaimer

The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking, sales and trading or principal trading revenues, however, compensation may relate to the revenues of UBS as a whole, of which investment banking, sales and trading and principal trading are a part.

Tax treatment depends on the individual circumstances and may be subject to change in the future. UBS does not provide legal or tax advice and makes no representations as to the tax treatment of assets or the investment returns thereon both in general or with reference to specific client's circumstances and needs. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein.

This material may not be reproduced or copies circulated without prior authority of UBS. Unless otherwise agreed in writing UBS expressly prohibits the distribution and transfer of this material to third parties for any reason. UBS accepts no liability whatsoever for any claims or lawsuits from any third parties arising from the use or distribution of this material. This report is for distribution only under such circumstances as may be permitted by applicable law. For information on the ways in which CIO manages conflicts and maintains independence of its investment views and publication offering, and research and rating methodologies, please visit [www.ubs.com/research](http://www.ubs.com/research).

Additional information on the relevant authors of this publication and other CIO publication(s) referenced in this report; and copies of any past reports on this topic; are available upon request from your client advisor.

**Important Information About Sustainable Investing Strategies:** Incorporating environmental, social and governance (ESG) factors or Sustainable Investing considerations may inhibit the portfolio manager's ability to participate in certain investment opportunities that otherwise would be consistent with its investment objective and other principal investment strategies. The returns on a portfolio consisting primarily of ESG or sustainable investments may be lower than a portfolio where such factors are not considered by the portfolio manager. Because sustainability criteria can exclude some investments, investors may not be able to take advantage of the same opportunities or market trends as investors that do not use such criteria. Companies may not necessarily meet high performance standards on all aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility, sustainability, and/or impact performance.

Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

**External Asset Managers / External Financial Consultants:** In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties. **Austria:** This publication is not intended to constitute a public offer under Austrian law, but might be distributed for information purposes to clients of UBS Europe SE, Niederlassung Österreich, with place of business at Wächtergasse 1, A-1010 Wien. UBS Europe SE, Niederlassung Österreich is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), to which this publication has not been submitted for approval. **Bahrain:** UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, clients have no protection under local banking and investment services laws and regulations. **Brazil:** Distributed by UBS Brasil Administradora de Valores Mobiliários Ltda. and/or by UBS Consenso Investimentos Ltda., entities regulated by Comissão de Valores Mobiliários ("CVM"). The views and opinions expressed in this report accurately reflect analyst's personal views about the subject securities and issuers. This report is only intended for Brazilian residents directly purchasing or selling securities in the Brazil capital market through a local authorized institution. For investors residing in Brazil, Eligible Investors are only those classified as Professional or Qualified Investors as per Brazilian regulation. Professional Investors are considered to be the following Brazilian resident investors: (i) financial institutions and other institutions authorized to operate by the Brazilian Central Bank, (ii) insurance firms and investment capital companies, (iii) open and closed ended pension funds, (iv) any individual or entity holding financial investments higher than R\$ 10.000.000 (ten million Brazilian Reais) and who additionally certifies in written form their/its status of professional investor, (v) investment funds, (vi) investment clubs managed by a portfolio manager authorized by CVM and (vii) independent investment agents, securities portfolio managers, securities analysts and securities consultants duly authorized by CVM, regarding their own investments. Qualified Investors are considered to be the following Brazilian resident investors: (i) professional investors, (ii) any individual or entity holding financial investments higher than R\$ 1.000.000 (one million Brazilian Reais) and who additionally certifies in written form their/its condition of qualified investor, (iii) individuals approved in a technical qualification examination or bearing a certification provided by CVM as independent investment agents, portfolio managers, securities analysts, and/or investment advisors/consultants with respect to their own investments, and (iv) investment clubs managed by one or more qualified investors. **Canada:** The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. In Canada, this publication is distributed by UBS Investment Management Canada Inc.. **China:** This research report is neither intended to be distributed to PRC investors nor to provide securities investment consultancy services within the territory of PRC. **Czech Republic:** UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment services in the Czech Republic. Please notify UBS if you do not wish to receive any further correspondence. **Denmark:** This publication is not intended to constitute a public offer under Danish law, but might be distributed by UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business at Sankt Annæ Plads 13, 1250 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under the No. 38 17 24 33. UBS Europe SE, Denmark Branch, filial af UBS Europe SE is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the BaFin, the central bank of Germany (Deutsche Bundesbank) and the Danish Financial Supervisory Authority (DFSA) (Finanstilsynet), to which this document has not been submitted for approval. **Egypt:** Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have not been and will not be registered with the Egyptian Financial Supervisory Authority (EFSA). **France:** This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of € 132.975.556, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution." **Germany:** This publication is distributed to clients of UBS Europe SE, with registered office at Bockenheimer Landstrasse 2-4, 60323 Frankfurt am Main, an entity supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht. **Greece:** UBS Switzerland AG and its affiliates (UBS) are not licensed as a bank or financial institution under Greek legislation and do not provide banking and financial services in Greece. Consequently, UBS provides such services from branches outside of Greece, only. This document may not be considered as a public offering made or to be made to residents of Greece. **Hong Kong:** This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. **Indonesia, Malaysia, Philippines, Thailand:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Any and all advice provided and/or trades executed by UBS pursuant to the material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. The material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. **India:** Distributed by UBS Securities India Private Ltd. 2/F, 2 North Avenue, Maker Maxity,

## Appendix

### Disclaimer

Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, BSE (Capital Market Segment) INB010951437. **Italy:** This publication is distributed to clients of UBS Europe SE, Succursale Italia, Via del Vecchio Politecnico, 3 - 20121 Milano, branch of UBS Europe SE, a German bank duly authorized by the "Bundesanstalt für Finanzdienstleistungsaufsicht" (BaFin) to the provision of financial services, supervised by both BaFin and "Consob". **Jersey:** UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place business is 1, IFC Jersey, St Helier, Jersey, JE2 3BX. **Luxembourg:** This publication is not intended to constitute a public offer under Luxembourg law, but might be distributed for information purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at 33A, Avenue J. F. Kennedy, L-1855 Luxembourg. UBS Europe SE, Luxembourg Branch is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin), and is subject to the joint supervision of BaFin, the central bank of Germany (Deutsche Bundesbank), as well as of the Luxembourg supervisory authority, the Commission de Surveillance du Secteur Financier (the "CSSF"), to which this publication has not been submitted for approval. **Mexico:** This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland AG, incorporated as a non-independent investment advisor under the Securities Market Law due to the relation with a Foreign Bank. UBS Asesores is a regulated entity and it is subject to the supervision of the Mexican Banking and Securities Commission ("CNBV"), which exclusively regulates UBS Asesores regarding the rendering of portfolio management, as well as on securities investment advisory services, analysis and issuance of individual investment recommendations, so that the CNBV has no surveillance faculties nor may have over any other service provided by UBS Asesores. UBS Asesores is registered before CNBV under Registry number 30060. You are being provided with this UBS publication or material because you have indicated to UBS Asesores that you are a Sophisticated Qualified Investor located in Mexico. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to which such analyst(s) render services. **Nigeria:** UBS Switzerland AG and its affiliates (UBS) are not licensed, supervised or regulated in Nigeria by the Central Bank of Nigeria (CBN) or the Nigerian Securities and Exchange Commission (SEC) and do not undertake banking or investment business activities in Nigeria. The investment products mentioned in this material are not being offered or sold by UBS to the public in Nigeria and they have not been submitted for approval nor registered with the Nigerian SEC. If you are interested in products of this nature, please let us know and we will direct you to someone who can advise you. The investment products mentioned in this material are not being directed to, and are not being made available for subscription by any persons within Nigeria other than the selected investors to whom the offer materials have been addressed as a private sale or domestic concern within the exemption and meaning of Section 69(2) of the Investments and Securities Act, 2007 (ISA). Portugal: UBS Switzerland AG is not licensed to conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the Portuguese regulators (Bank of Portugal "Banco de Portugal" and Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). **Russia:** This document or information contained therein is for information purposes only and constitute neither a public nor a private offering, is not an invitation to make offers, to sell, exchange or otherwise transfer any financial instruments in the Russian Federation to or for the benefit of any Russian person or entity and does not constitute an advertisement or offering of securities in the Russian Federation within the meaning of Russian securities laws. **Singapore:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Clients of UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. Spain: This publication is distributed to its clients by UBS Europe SE, Sucursal en España, with registered office at Calle María de Molina 4, C.P. 28006, Madrid, entity supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and Banco de España, to which this publication has not been submitted for approval. Additionally it is authorized to provide investment services on securities and financial instruments, regarding which it is supervised by the Comisión Nacional del Mercado de Valores (CNMV) as well. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea duly authorized and regulated by BaFin. **Sweden:** This publication is not intended to constitute a public offer under Swedish law, but might be distributed by UBS Europe SE, Sweden Bankfilial with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden, registered with the Swedish Companies Registration Office under the Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin). UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the BaFin, the central bank of Germany (Deutsche Bundesbank) and the Swedish financial supervisory authority (Finansinspektionen), to which this document has not been submitted for approval. **Taiwan:** This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. **Turkey:** No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey in the Republic of Turkey. UBS Switzerland AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 6362). Accordingly neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 there is no restriction on the purchase or sale of the instruments by residents of the Republic of Turkey. **UAE:** UBS is not licensed in the UAE by the Central Bank of UAE or by the Securities & Commodities Authority. The UBS AG Dubai Branch is licensed in the DIFC by the Dubai Financial Services Authority as an authorised firm. UK: Approved by UBS Switzerland AG, authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS Switzerland AG is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to retail clients of UBS London in the UK. Where products or services are provided from outside the UK, they will not be covered by the UK regulatory regime or the Financial Services Compensation Scheme. **Ukraine:** UBS is not registered and licensed as a bank/financial institution under Ukrainian legislation and does not provide banking and other financial services in Ukraine. UBS has not made and will not make any offer of the mentioned products to the public in Ukraine. No action has been taken to authorize an offer of the mentioned products to the public in Ukraine and the distribution of this document shall not constitute financial services for the purposes of the Law of Ukraine "On Financial Services and State Regulation of Financial Services Markets" dated 12 July 2001. Accordingly, nothing in this document or any other document, information or communication related to the mentioned products shall be interpreted as containing an offer or invitation to offer, or solicitation of securities in the territory of Ukraine. Electronic communication must not be considered as an offer to enter into an electronic agreement or electronic instrument within the meaning of the Law of Ukraine "On Electronic Commerce" dated 3 September 2015. This document is strictly for private use by its holder and may not be passed on to third parties or otherwise publicly distributed.

Version 02/2019. CIO82652744

© UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.